Under accelerated assessment status, the European Medicines Agency (EMA) has accepted for review GlaxoSmithKline’s (NYSE:GSK)
marketing application seeking approval to use antibody-drug conjugate
belantamab mafodotin to treat patients with relapsed/refractory multiple
myeloma whose prior therapy included an immunomodulatory agent, a
proteasome inhibitor and an anti-CD38 antibody.
Belantamab mafodotin consists of a humanized
anti-B cell maturation antigen monoclonal antibody linked to a cytotoxic
agent called auristatin F.
https://seekingalpha.com/news/3537269-ema-accepts-glaxo-application-for-antibody-drug-conjugate-for-multiple-myeloma
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.